Literature DB >> 3467111

Establishment of a cisplatin-resistant human ovarian cancer cell line.

Y Kikuchi, M Miyauchi, I Kizawa, K Oomori, K Kato.   

Abstract

A cisplatin-resistant cell line was established by use of KF-1 cells derived from human serous cystadenocarcinoma of the ovary. This resistant cell line, designated "KFr," was capable of proliferating in the presence of 1.0 micrograms cisplatin/ml. It had doubling times of 24.8 and 27.2 hours in the presence of 0.5 and 1.0 micrograms cisplatin/ml, respectively. The KFr cells had lactate dehydrogenase (LDH) activities about fourfold higher than those of the parent KF-1 cells. Analysis of the isozymes of the KFr cells revealed that they had a faint LDH-3 band in addition to LDH-4, the only stained band in the parent KF-1 cells. The morphologic characteristics of the KFr cells were an enlarged nucleus and prominent nucleoli, unlike the nucleus and nucleoli of the parent KF-1 cells. The degree of resistance to cisplatin of the KFr cells was about twenty-fold higher than that of the KF-1 cells, with regard to the concentrations of cisplatin required for 50% inhibition of cell proliferation. However, when 5 microM calmodulin antagonists [N-(6-aminohexyl)-1-naphthalenesulfonamide or N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide] were added in the presence of concentrations of cisplatin that hardly inhibited cell proliferation, the KFr cell proliferation was markedly inhibited. These results suggest that cisplatin resistance can be overcome by calmodulin antagonists.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3467111

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  16 in total

1.  Development of alkylating agent-resistant human tumor cell lines.

Authors:  B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.

Authors:  Hiroaki Soyama; Morikazu Miyamoto; Masashi Takano; Tadashi Aoyama; Hiroko Matsuura; Takahiro Sakamoto; Kazuki Takasaki; Mika Kuwahara; Kento Kato; Tomoyuki Yoshikawa; Hideki Iwahashi; Hitoshi Tsuda; Kenichi Furuya
Journal:  Med Oncol       Date:  2017-11-22       Impact factor: 3.064

3.  Competitive binding of Rab21 and p120RasGAP to integrins regulates receptor traffic and migration.

Authors:  Anja Mai; Stefan Veltel; Teijo Pellinen; Artur Padzik; Eleanor Coffey; Varpu Marjomäki; Johanna Ivaska
Journal:  J Cell Biol       Date:  2011-07-18       Impact factor: 10.539

4.  High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.

Authors:  M Miyamoto; M Takano; K Iwaya; N Shinomiya; T Goto; M Kato; A Suzuki; T Aoyama; J Hirata; I Nagaoka; H Tsuda; K Furuya
Journal:  Br J Cancer       Date:  2015-01-27       Impact factor: 7.640

5.  Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells.

Authors:  H Nakata; Y Kikuchi; T Tode; J Hirata; T Kita; K Ishii; K Kudoh; I Nagata; N Shinomiya
Journal:  Jpn J Cancer Res       Date:  1998-07

6.  Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET.

Authors:  T Mitamura; H Watari; L Wang; H Kanno; M K Hassan; M Miyazaki; Y Katoh; T Kimura; M Tanino; H Nishihara; S Tanaka; N Sakuragi
Journal:  Oncogenesis       Date:  2013-03-25       Impact factor: 7.485

7.  The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers.

Authors:  T Goto; M Takano; J Hirata; H Tsuda
Journal:  Br J Cancer       Date:  2008-03-04       Impact factor: 7.640

8.  Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.

Authors:  S M Castellino; H S Friedman; G B Elion; E T Ong; S L Marcelli; R Page; D D Bigner; M W Dewhirst
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

9.  Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines.

Authors:  K Terasawa; M Toyota; S Sagae; K Ogi; H Suzuki; T Sonoda; K Akino; R Maruyama; N Nishikawa; K Imai; Y Shinomura; T Saito; T Tokino
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

10.  Functional Analyses of RUNX3 and CaMKIINα in Ovarian Cancer Cell Lines Reveal Tumor-Suppressive Functions for CaMKIINα and Dichotomous Roles for RUNX3 Transcript Variants.

Authors:  Karolin Heinze; Daniel Kritsch; Alexander S Mosig; Matthias Dürst; Norman Häfner; Ingo B Runnebaum
Journal:  Int J Mol Sci       Date:  2018-01-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.